WALTHAM, Mass. / May 04, 2023 / Business Wire / Vicarious Surgical, Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced that the company earned recognition from Fast Company and the MedTech Breakthrough Awards for two industry awards:
“It is an honor to see our work recognized by peers and colleagues as we continue to meet milestones on the path to commercializing our unique surgical robotic platform,” said Adam Sachs, Chief Executive Officer of Vicarious Surgical. “As a company, we have made significant strides in establishing strategic hospital system partnerships and completing our Beta 2 surgical system. It is encouraging to join other true innovators in each of these two industry awards.”
The latest award recognition comes on the heels of TIME naming the Vicarious Surgical robotic system one of their Best Inventions of 2022. The device was recognized in the experimental inventions category of TIME’s annual list, which features 200 extraordinary innovations changing lives.
About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next generation robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.
Last Trade: | US$9.03 |
Daily Volume: | 0 |
Market Cap: | US$47.410M |
November 12, 2024 August 12, 2024 August 07, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB